Related Experiment Video
Updated: Jun 20, 2026

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
Drug interactions in oncology: how common are they?
R P Riechelmann1, A Del Giglio
1Internal Medicine, Federal University of Sao Paulo, Sao Paulo, Brazil. rachelri@terra.com.br
Background:
Drug-drug interactions (DDIs) comprise an important problem in medical oncology practice. We systematically reviewed the frequency of DDIs in oncology.
Methods:
We searched PubMed for eligible articles and on-line databases for abstracts of major oncology meetings.
Results:
Eight studies reported on the frequency of DDIs: six evaluated the frequency of potential DDIs, while two studies reported on real DDIs, i.e. interactions that had clinical consequences. Studies of potential DDIs found that approximately one-third of patients are exposed to dangerous drug doublets, with the most common ones involving warfarin and anticonvulsants. One study of real DDIs found that 2% of hospitalized cancer patients had a DDI as the cause of admission.
Conclusions:
Drug interactions comprise an important issue in oncology, with approximately one-third of ambulatory cancer patients being at risk of DDIs. Data are limited on the clinical consequences of drug interactions among cancer patients.
Insights
Approximately one-third of cancer patients face risks from drug-drug interactions (DDIs). While potential DDIs are common, data on their clinical impact in oncology remains limited.
Area of Science:
- Oncology
- Pharmacology
- Clinical Medicine
Background:
- Drug-drug interactions (DDIs) represent a significant challenge in medical oncology.
- Systematic review of DDI frequency in cancer patients is crucial for patient safety.
Purpose of the Study:
- To systematically review the existing literature on the frequency of drug-drug interactions in oncology.
- To assess the prevalence of both potential and clinically consequential DDIs in cancer care.
Main Methods:
- Searched PubMed for eligible articles.
- Included abstracts from major oncology meetings to capture recent findings.
Main Results:
- Eight studies reported DDI frequencies.
- One-third of patients exposed to potential DDIs, commonly involving warfarin and anticonvulsants.
- 2% of hospitalized cancer patients admitted due to a DDI.
Conclusions:
- A substantial proportion of ambulatory cancer patients are at risk of DDIs.
- Limited data exists regarding the clinical consequences of DDIs in this population.
More Related Videos
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
Related Concept Videos
Drug toxicity: Drug–Drug Interaction
Pharmacokinetics: Drug–Drug Interactions
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combined Effects of Drugs: Antagonism
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...